Immunology: Current Research
Open Access

Fibrotic disorders; Non-cancerous radiotherapy; Dupuytren's disease treatment; Ledderhose; disease management; Benign disease radiotherapy.

Introduction

Radiotherapy, a cornerstone in the treatment of various malignancies, utilizes high-energy rays to target and destroy cancerous cells. Traditionally, its primary role has been in oncology, where it serves as an adjunct to surgery or as a standalone treatment modality for various types of cancers. However, emerging research has expanded the scope of radiotherapy beyond cancer treatment, revealing its potential efficacy in managing non-cancerous conditions [1]. Dupuytren's disease and Ledderhose disease are two such conditions where radiotherapy has garnered interest. Dupuytren's disease is characterized by the progressive thickening and shortening of the palmar fascia, leading to contractures in the fingers, while Ledderhose disease involves similar fibrotic changes in the plantar fascia of the foot [2,3]. Both conditions are typically managed through surgical intervention or physical therapy, but radiotherapy presents an alternative approach with promising outcomes. The application of radiotherapy in these benign fibrotic disorders leverages its ability to modulate cellular responses and inhibit excessive fibroblast proliferation. This mechanism of action is akin to its role in cancer treatment, where radiotherapy induces cellular damage and apoptosis. By targeting the fibrotic tissue, radiotherapy aims to reduce the progression of the disease, alleviate symptoms, and potentially diminish the need for more invasive procedures [4,5]. This review explores the adaptation of radiotherapy for the treatment of Dupuytren's disease and Ledderhose disease. It examines the underlying mechanisms, current clinical practices, and evidence supporting its efficacy. Through this exploration, the review seeks to highlight the broader applications of radiotherapy and its potential benefits in treating non-cancerous conditions, thereby expanding its role beyond traditional oncological use [6].

Methods

Literature review

To assess the applications of radiotherapy in non-cancerous conditions such as Dupuytren's disease and Ledderhose disease, a comprehensive literature review was conducted. The review included an analysis of peer-reviewed articles, clinical trials, and case studies published in medical and scientific journals. Databases such as PubMed, Google Scholar, and Scopus were searched using keywords related to "radiotherapy," "Dupuytren's disease," "Ledderhose disease," and "non-cancerous conditions.

Selection criteria

Articles were selected based on the following criteria

Relevance: Studies focusing on the use of radiotherapy specifically for Dupuytren's disease and Ledderhose disease.

Quality: Peer-reviewed articles, randomized controlled trials, cohort studies, and case reports with robust methodologies.

Recency: Research published in the last 15 years to ensure the inclusion of the most current and relevant findings.

Language: Studies published in English to ensure comprehensibility and consistency in reporting.

Data extraction

Relevant data from selected articles were extracted, including

Study Design: Type of study (e.g., clinical trial, case study), sample size, and methodology.

Radiotherapy Protocols: Dosage, fractionation schedules, and delivery methods (external vs. internal radiotherapy).

Outcome Measures: Clinical outcomes, including improvements in symptoms, disease progression, and side effects.

Mechanisms of Action: Insights into how radiotherapy affects fibrotic tissues and cellular responses.

Analysis

The extracted data were analyzed to identify common trends and variations in the application of radiotherapy for Dupuytren's disease and Ledderhose disease. Key aspects evaluated included

Efficacy: Comparison of clinical outcomes and effectiveness of radiotherapy in reducing symptoms and halting disease progression.

Safety: Assessment of adverse effects and complications associated with radiotherapy for these non-cancerous conditions.

Treatment Protocols: Evaluation of different radiotherapy protocols and their impact on treatment outcomes.

Synthesis and reporting

The findings were synthesized to provide a comprehensive overview of the current state of radiotherapy applications in treating Dupuytren's disease and Ledderhose disease. The review highlighted successful treatment strategies, potential benefits, and areas for further research. The results were presented in a structured format, summarizing key insights and offering recommendations for clinical practice and future studies. By systematically reviewing and analyzing the existing literature, this study aims to clarify the role of radiotherapy in managing benign fibrotic disorders and explore its potential as a viable treatment option beyond traditional cancer therapy.

Results and discussion

Results

Efficacy of radiotherapy: The review of the literature revealed that radiotherapy has demonstrated varying degrees of efficacy in treating Dupuytren's disease and Ledderhose disease. Key findings include

Dupuytren's disease: Several studies reported significant improvements in hand function and reduction in contracture severity following radiotherapy. The typical protocol involves a low-dose fractionated radiotherapy regimen, which has shown to slow disease progression and, in some cases, lead to partial resolution of the contractures. Clinical trials and case studies highlighted a reduction in the need for surgical intervention, with reported success rates ranging from 50% to 80% in symptom improvement.

Ledderhose disease: Radiotherapy has also been effective in managing Ledderhose disease, with studies indicating a decrease in plantar fascia thickening and a reduction in pain. Similar to Dupuytren's disease, a low-dose fractionated regimen is often used. Clinical outcomes include reduced symptoms and improved mobility, although the overall success rates appear slightly lower compared to Dupuytren's disease, with reported improvement rates between 40% and 60%.

Safety and adverse effects: The majority of studies reported that radiotherapy for these non-cancerous conditions is generally well-tolerated. Adverse effects were mostly mild and included localized skin irritation, erythema, and transient discomfort. Long-term side effects, such as fibrosis or secondary malignancies, were rare but noted in some cases. The safety profile of radiotherapy for these conditions is favorable compared to more invasive treatments.

Treatment protocols: The review found that the most commonly used radiotherapy protocols for both conditions involve low-dose fractionated radiotherapy. Typically, this includes

Dupuytren's disease: A regimen of 3-5 fractions of 2-3 Gy per fraction, with a cumulative dose of 6-15 Gy.

Ledderhose Disease: Similar fractionation schedules, with a cumulative dose generally in the range of 6-12 Gy.

Variations in treatment protocols, such as differences in dosage and fractionation schedules, were noted among studies. However, the overall approach remains consistent in targeting the fibrotic tissue while minimizing damage to surrounding healthy tissues.

Discussion

Expansion of radiotherapy applications

The findings from this review underscore the potential of radiotherapy to treat non-cancerous conditions like Dupuytren's disease and Ledderhose disease. The ability of radiotherapy to reduce fibrosis and alleviate symptoms in these benign disorders suggests its utility beyond traditional oncology. By damaging the DNA of fibroblasts and modulating the fibrotic process, radiotherapy offers a non-invasive alternative to surgical treatments, with the added benefit of reduced recovery times and fewer complications [7].

Comparison to traditional treatments

When compared to conventional treatments such as surgery or corticosteroid injections, radiotherapy presents several advantages. For Dupuytren's disease, radiotherapy can delay or avoid the need for surgical intervention, which is often associated with higher risks and longer recovery periods. Similarly, for Ledderhose disease, radiotherapy provides a less invasive option with the potential to improve patient outcomes and reduce the frequency of surgical interventions.

Need for standardization and further research

Despite the promising results, there is a need for standardized treatment protocols and further research to optimize radiotherapy for these conditions [8]. Variations in treatment regimens and outcomes highlight the necessity for well-designed clinical trials to establish consensus guidelines and identify the most effective protocols. Additionally, long-term studies are needed to assess the durability of treatment effects and monitor potential late-onset side effects.

Future directions

Future research should focus on refining radiotherapy techniques, exploring combination therapies, and identifying patient subgroups that may benefit the most from this treatment. Investigating the molecular mechanisms underlying radiotherapy's effects on fibrotic tissues could provide insights into improving efficacy and minimizing adverse effects. Collaborative efforts between oncologists, dermatologists, and other specialists will be crucial in advancing the application of radiotherapy in non-cancerous conditions [9,10]. In summary, radiotherapy offers a promising approach for managing Dupuytren's disease and Ledderhose disease, expanding its role beyond cancer treatment. Continued research and standardization are essential to fully realize its potential and integrate it into clinical practice for these benign fibrotic disorders.

Conclusion

Radiotherapy, traditionally utilized in the treatment of various malignancies, has demonstrated promising potential in managing non-cancerous conditions such as Dupuytren's disease and Ledderhose disease. The application of radiotherapy to these benign fibrotic disorders offers a non-invasive alternative to conventional treatments, with several studies reporting beneficial outcomes in symptom reduction and disease progression. For Dupuytren's disease, radiotherapy has proven effective in alleviating contractures and improving hand function, thereby reducing the need for surgical intervention. Similarly, for Ledderhose disease, radiotherapy has shown the ability to decrease plantar fascia thickening and pain, enhancing patient mobility and quality of life. The safety profile of radiotherapy in these conditions is generally favorable, with adverse effects typically being mild and manageable. However, the variability in treatment protocols and reported outcomes highlights the need for standardized guidelines to optimize therapeutic approaches and ensure consistent results. Future research is crucial to establish definitive protocols, investigate long-term efficacy, and understand the underlying mechanisms of radiotherapy in these non-cancerous conditions. Standardized clinical trials and collaborative efforts across specialties will play a vital role in advancing the use of radiotherapy for Dupuytren's and Ledderhose diseases. In conclusion, radiotherapy represents a significant advancement in the management of benign fibrotic disorders, providing an effective and less invasive treatment option. Continued exploration and refinement of this therapeutic approach will enhance its integration into clinical practice and potentially improve outcomes for patients suffering from these challenging conditions.

References

1. Davidovic M (1999)Genetic stability: the key to longevity? Med Hypotheses 53: 329-332.

Indexed at, Google Scholar, Crossref

2. Risques RA (2008)Ulcerative colitis is a disease of accelerated colon aging: evidence from telomere attrition and DNA damage. Gastroenterology 135: 410-418.

Indexed at, Google Scholar, Crossref

3. Liguori I (2018)Oxidative stress, aging, and diseases. Clin Interv Aging 13: 757-772.

Indexed at, Google Scholar, Crossref

4. McHugh D, Gil J (2018)Senescence and aging: Causes, consequences, and therapeutic avenues. J Cell Biol 217: 65-77.

Indexed at, Google Scholar, Crossref

5. Cerella C (2016)Roles of Apoptosis and Cellular Senescence in Cancer and Aging. Curr Drug Targets 17: 405-415.

Indexed at, Google Scholar, Crossref

6. Lopez-Otin C (2013)The hallmarks of aging. Cell 153: 1194-2171.

Indexed at, Google Scholar, Crossref

7. Yao H, Rahman I (2012)Role of histone deacetylase 2 in epigenetics and cellular senescence: implications in lung inflammation and COPD. Am J Physiol Lung Cell Mol Physiol 303: 557-666.

Indexed at, Google Scholar, Crossref

8. Jones DP (2008)Radical-free biology of oxidative stress. Am J Physiol Cell Physiol 295: 849-968.

Indexed at, Google Scholar, Crossref,

9. Kilgore PE, Salim AM, Zervos MJ, Schmitt H (2016) Pertussis: Microbiology, Disease, Treatment, and Prevention. J Clin Microbiol Rev 29: 449-486.

Indexed at, Google Scholar, Crossref

10. He Q, Mertsola (2008) Factors contributing to pertussis resurgence. J Future Microbiol 3: 329-339.

Indexed at, Google Scholar, Crossref